Back Pain News and Research

Latest Back Pain News and Research

Patients with RLS using rotigotine achieve sustained improvements

New data presented at the 62nd American Academy of Neurology annual meeting in Toronto, Canada, showed that patients with moderate to severe Restless Legs Syndrome using rotigotine achieved sustained improvements in symptoms over 5 years of treatment.

15 Apr 2010

New findings point to potential dysfunctional learning process in chronic pain patients

New research reveals why a stimulus that healthy human subjects perceive as a reward might be processed quite differently in the brains of humans suffering from chronic pain.

15 Apr 2010

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Baxter International Inc. and New York-Presbyterian Hospital/Weill Cornell Medical Center today announced results of an 18-month Phase II clinical study of GAMMAGARD LIQUID and GAMMAGARD S/D [Immune Globulin Intravenous (Human)] (marketed as KIOVIG outside of the U.S.) for mild-to-moderate Alzheimer's disease. This marked the first announcement of clinical trial results measuring function and cognition in patients who received uninterrupted GAMMAGARD for a period of 18 months.

From Baxter International Inc. 15 Apr 2010

Study suggests patients with low-back pain may benefit from chiropractic treatment

Low-back pain sufferers can seek relief from any number of health professionals, orthopedists, physical therapists and osteopaths among them.

15 Apr 2010

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Acorda Therapeutics, Inc. today announced that four new analyses of clinical trial data on AMPYRA™ (dalfampridine) Extended Release Tablets 10 mg are being presented at the 62nd American Academy of Neurology Annual meeting.

13 Apr 2010

Health care experts brand plan for a “Big Australia” as disaster waiting to happen

Increased immigration rates are set to make Australia’s population hit 36 million by the year 2050 according to Federal Government estimates. This would be a huge leap from the present 22,300,000 people that the nation has today. The added population is being seen as a necessity to ensure economical survival for the country.

13 Apr 2010

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Talecris Biotherapeutics, Inc., today announced results of a new survey showing that Gamunex® (Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified) is the preferred immune globulin intravenous (IGIV) among neurologists who indicated a brand preference. In the survey, conducted online by Harris Interactive® on behalf of Talecris, neurologists selected Gamunex over four times more often than all other available liquid IGIV therapies, with a statistically significant margin (p<0.05).

13 Apr 2010

Complex back surgeries skyrocket, raising concerns about cost, complications

NPR: "Too many complex back surgeries are being done and people are suffering as a result, according to a study in the current issue of the Journal of the American Medical Association. The general tendency noted in the study — that many patients and doctors think more medical care is always better — has implications for the new health overhaul law.

8 Apr 2010

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

DURECT Corporation announced today that its licensee, King Pharmaceuticals, has begun a Phase IIb clinical trial to evaluate ELADUR™ (TRANSDUR™-Bupivacaine) for the treatment of chronic low back pain. ELADUR is an investigational transdermal drug patch intended to deliver bupivacaine for up to 3 days from a single application.

7 Apr 2010

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Orthopedic surgeons are often hamstrung by less-than-ideal grafting material when performing surgeries for complex bone injuries resulting from trauma, aging or cancer. Conventional synthetic bone grafts are typically made of stiff polymers or brittle ceramics, and cannot readily conform to the complex and irregular shapes that often result from injury; in addition, they often require metallic fixation devices that require open surgeries to insert and remove.

6 Apr 2010

Sunshine vitamin cures common health problems

What do obesity, heart disease, depression, diabetes, and fibromyalgia have in common? The answer is vitamin D deficiency. More than 200 million Americans lack this essential vitamin and as a result suffer from a host of daily annoyances, chronic conditions, and even life-threatening illnesses.

2 Apr 2010

Lifetime Television to feature XenaCare Holdings' OTC pain reliever Cobroxin

XenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer healthcare products, has announced today that its over-the-counter (OTC) pain reliever, Cobroxin, will be featured on a segment of The Balancing Act, a morning show that airs on the top-rated women's cable television network, Lifetime Television.

1 Apr 2010

Study comparing Plasma Disc Decompression with epidural steroid injections for lumbar disc herniation

ArthroCare Corp., a leader in developing state-of-the-art, minimally invasive surgical products, announced today the publication of an important clinical trial demonstrating that patients treated with ArthroCare's Plasma Disc Decompression (PDD) products experienced reduced pain and better quality of life scores compared to patients treated with the current standard care, epidural steroid injections.

31 Mar 2010

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy, HIV and Multiple Sclerosis, has announced today that its over-the-counter pain reliever, Cobroxin, is now available for purchase in CVS.

31 Mar 2010

Enrollment complete in Paradigm Spine's comparative study of coflex interlaminar technology

Paradigm Spine, LLC, a developer of innovative non-fusion and fusion spinal implant solutions, announced today that it has completed patient enrollment in an Investigational Device Exemption pivotal clinical study comparing the coflex® interlaminar technology to instrumented posterolateral fusion in the surgical treatment of spinal stenosis.

30 Mar 2010

IQWiG: Not all forms of massage therapy proven to help against low back pain

Most people have experienced back pain - and many hope that massage will relieve it. But not all forms of massage have been scientifically proven to help against low back pain. That is what the German Institute for Quality and Efficiency in Health Care pointed out in information published on informedhealthonline.org today.

27 Mar 2010

WinRho SDF for ITP: Cangene announces new safety information

Cangene Corporation, in consultation with Health Canada, is informing Canadian patients and healthcare professionals of important new safety information concerning the use of WinRho SDF (Rho (D) Immune Globulin (Human)) for the treatment of immune thrombocytopenic purpura, also called immune thrombocytopenia, or ITP. WinRho SDF belongs to a group of biological medicines derived from human plasma known as immunoglobulins. It is administered in hospitals by infusion through the veins.

27 Mar 2010

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

Acorda Therapeutics, Inc. today announced that the Company has submitted applications to extend patent protection for AMPYRA™ (dalfampridine) Extended Release Tablets, 10 mg to the United States Patent and Trademark Office.

22 Mar 2010

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

CytoDyn, Inc. has begun full humanization of Cytolin®, the Company’s unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.

17 Mar 2010

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Zogenix, Inc., a privately held pharmaceutical company, announced that it has initiated a pivotal Phase 3 clinical trial with ZX002, a novel, oral, controlled-release formulation of hydrocodone without acetaminophen. ZX002 is being developed for the treatment of moderate to severe pain in individuals who require around-the-clock opioid therapy for the control of pain.

17 Mar 2010

Back Pain News and Research

Latest Back Pain News and Research

Patients with RLS using rotigotine achieve sustained improvements

New findings point to potential dysfunctional learning process in chronic pain patients

Phase II GAMMAGARD clinical study for Alzheimer's disease: 18-month results announced

Study suggests patients with low-back pain may benefit from chiropractic treatment

Clinical trial data on AMPYRA Extended Release Tablets to be presented at AAN Annual meeting

Health care experts brand plan for a “Big Australia” as disaster waiting to happen

Survey reveals Gamunex as preferred IGIV therapy among neurologists

Complex back surgeries skyrocket, raising concerns about cost, complications

King Pharmaceuticals commences Phase IIb clinical trial of ELADUR for chronic low back pain

Nanoparticle-core polymer holds promise as weight-bearing replacement for traditional graft materials

Sunshine vitamin cures common health problems

Lifetime Television to feature XenaCare Holdings' OTC pain reliever Cobroxin

Study comparing Plasma Disc Decompression with epidural steroid injections for lumbar disc herniation

Nutra Pharma's Cobroxin pain reliever now available at CVS stores

Enrollment complete in Paradigm Spine's comparative study of coflex interlaminar technology

IQWiG: Not all forms of massage therapy proven to help against low back pain

WinRho SDF for ITP: Cangene announces new safety information

Acorda Therapeutics submits applications to extend patent protection for AMPYRA to USPTO

CytoDyn commences full humanization of Cytolin immune therapy for treating HIV/AIDS

Zogenix announces the initiation of pivotal Phase 3 clinical trial with ZX002

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Back Pain News and Research

Latest Back Pain News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in